PROCEEDING

Aripiprazole, a novel antipsychotic agent : Dopamine D₂ receptor partial agonist

Tsuyoshi Hirose, and Tetsuro Kikuchi

Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan

Abstract : It is obvious that DA is an important neurotransmitter *in vivo*. It is involved in a variety of physiological processes such as mental processes, motor function and hormone regulation. In this context, it is quite understandable that a DA D₂ receptor antagonist that inhibits the DA D₂ receptor regardless of the state of activity of dopaminergic neurotransmission and inhibit the physiological function of DA can have a variety of adverse effects. In contrast to DA D₂ antagonists, aripiprazole acts as an antagonist at the DA D₂ receptor in the state of excessive dopaminergic neurotransmission, while it acts as an agonist at the DA D₂ receptor in the state of low dopaminergic neurotransmission, and thus attempts to bring the state of dopaminergic neurotransmission to normal. This activity of aripiprazole to regulate dopaminergic neurotransmission is physiologically reasonable, and can be regarded as a stabilizing effect, for which aripiprazole is called a dopamine system stabilizer J. Med. Invest. 52 Suppl. : 284-290, November, 2005

Keywords : aripiprazole, dopamine D² receptor partial agonist, antipsychotic, schizophrenia

INTRODUCTION

Schizophrenia is a mental illness that appears from the adolescent period. Its morbidity rate is estimated at about 1% of the population with no interracial differences. It is now characterized as a illness that progresses repeating the relapse-remission cycle, and a collapse of personality occurs in severe cases. It consists of two major symptoms. One is the “positive symptoms” that express such abnormal behavior as defined in the following diagnostic terms: “hallucination,” “delusion,” and “agitation.” The other is the “negative symptoms” that are classified using the following diagnostic terms: “blunted affect,” “emotional withdrawal,” and “apathy.” In addition, the “positive symptoms” mostly emerge at an acute phase of the illness, and the “negative symptoms” generally emerge at its chronic phase (1) . The cause

and pathophysiological basis of schizophrenia are currently unclear, and various hypotheses about the cause have been proposed, for example, genetic disorder, neuro-developmental disorder from infancy, disorder of glutamatergic neurotransmission, and dopaminergic neuronal disorder, and so on. However, there is no hypothesis at present that sufficiently explains the pathophysiological and neurobiological basis (2) . Schizophrenic patients are now treated with typical and atypical antipsychotic agents in clinics, which have an antagonistic effect at dopamine (DA) D₂ receptors.

Fifty years has passed since the initial report of the antipsychotic activity of chlorpromazine in 1952. The cause of schizophrenia still remains unknown but has been hypothesized to be excessive activity of dopaminergic neurotransmission, and in the mid 1970s, the “DA hypothesis of schizophrenia” was proposed (3) . Based on this hypothesis, many DA receptor antagonists were developed. It is generally known that these so-called typical antipsychotics are effective against the positive symptoms, but have weak activity against the negative symptoms.

Received for publication September 9, 2005 ; accepted September 16, 2005.

Address correspondence and reprint requests to Tsuyoshi Hirose, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno Kawauchi-cho, Tokushima 770-0192, Japan and Fax : +81-88-665-6106

In terms of safety, this class of drugs is associated with extrapyramidal side effects such as akathisia, dystonia and parkinsonian movement disorders, as well hyperprolactinemia (4, 5). In the late 1980's, while the DA hypothesis itself was being modified (6, 7), there were additional proposals that other neural systems such as the serotonergic system and glutamatergic system may also be involved in the pathogenesis of schizophrenia, thus complicating the hypothesis that schizophrenia is due to abnormalities in DA neurotransmission (8). New drugs developed in the 1990s were clozapine, which established the concept of atypical antipsychotics, risperidone, which is a serotonin-dopamine antagonist (SDA), olanzapine and quetiapine, and in 2000, ziprasidone was introduced. Among the shortcomings of the typical antipsychotics, these antipsychotics largely solved the problem of extrapyramidal side effects (8, 9). However, on the other hand, the atypical antipsychotics are associated with problems of weight gain, lipid metabolism abnormalities, excessive sedation, and cardiac QT prolongation, so that there has existed a need for antipsychotics with better safety and tolerability.

At Otsuka Pharmaceuticals, based on the DA hypothesis, we have focused on drug discovery for compounds with inhibitory activity on the dopaminergic neurotransmission, which are different from the traditional agents, and have studied DA autoreceptor agonists since the 1970s. We have focused on agents to regulate neurotransmission, which act as agonists at the presynaptic DA autoreceptor and as antagonists at the postsynaptic DA D₂ receptor, and as a result developed aripiprazole, which is a DA D₂ receptor partial agonist (10-12). Aripiprazole was approved by the US FDA in November 2002 for schizophrenia and in the expanded 25 countries in the Europe by the European Commission (EC) in June 2004. Additionally in September 2004, it received a supplemental approval for the indication of acute manic episode of bipolar disorder by FDA. An application for approval is currently pending in Japan for schizophrenia as an indication. Aripiprazole is a small molecule with 3, 4-dihydro-2-(1H)-quinolinone as the backbone (Figure 1) and has attracted attention as the world's first novel antipsychotic that is a DA D₂ receptor partial agonist (13-15). In this review, we discuss the activity of aripiprazole as a DA D₂ receptor partial agonist and

discuss the utility of DA D₂ receptor partial agonists in schizo-phrenia.

DA D₂ RECEPTOR PARTIAL AGONIST ACTIVITY

Substances that bind specifically to the receptor, such as neurotransmitter, hormones or centrally acting drugs are called ligands. The concept of a partial agonist is not a new concept but has been in existence for a long time as a concept that explains the reactions mediated by ligands bound to the receptor and the receptor. Simply, a DA D₂ receptor partial agonist has affinity toward the DA D₂ receptor and an intrinsic activity that is less than the activity of the endogenous full agonist DA (that is, it can bind to the DA D₂ receptor and cause a similar set of reaction but the magnitude of the reaction is smaller than DA). These effects differ from the traditional typical and atypical DA D₂ receptor antagonists. The partial agonist activity of aripiprazole at the DA D₂ receptor has been demonstrated in the 4 *in vitro* and *ex vivo* studies described below.

1) An *in vitro* receptor binding study was conducted using a Chinese hamster ovary (CHO) cell membrane expressing the recombinant human DA D₂ receptor. The DA D₂ receptor agonist had higher affinity to the DA D₂ receptor in the G-protein-coupled state when compared to the DA D₂ receptor in the G-protein-uncoupled states (16). Aripiprazole differs from the DA D₂ receptor antagonist haloperidol and as with the DA D₂ receptor partial agonist terguride, has about a 2-fold higher affinity to the DA D₂ receptor in the G-protein-coupled state than that in the G-protein-uncoupled state. In addition, aripiprazole had far higher affinity to the DA D₂ receptor compared to the endogenous neuro-transmitter DA (Table 1) (10). These data suggest that aripiprazole is a DA D₂ receptor partial agonist.

2) Studies were conducted *in vitro* with CHO cell line expressing the recombinant human DA D₂ receptor (10) and rat primary cultures of anterior pituitary cells (unpublished). In both studies, the aripiprazole stimulated the DA D₂ receptor and the maximum stimulatory effect was smaller than the full agonist DA. In the studies conducted with the CHO cells expressing the recombinant human DA D₂ receptor, aripiprazole antagonized the stimulatory effect of DA to the level of aripiprazole (10) (Figure 2). These data indicate that the aripiprazole is a partial agonist with intrinsic activity that is less than the full agonist.

Figure 1 Structural formula of aripiprazole

Table 1 Affinity of antipsychotics to dopamine D_{2L} receptor in the G-protein-coupled or uncoupled state

Drug		Ki value (nM)		
		[¹²⁵ I]-7-OH-PIPAT (A)	[³ H]-Spiperone (B)	Ki (B) / Ki (A)
Agonist	Quinpirole	9.5 ± 1.5	634 ± 151	67
	Dopamine	17 ± 1.0	576 ± 192	34
Partial agonist	S-(-)-3-PPP	56 ± 4.5	1034 ± 231	18
	Terguride	0.16 ± 0.01	0.36 ± 0.04	2
	Aripiprazole	0.34 ± 0.02	0.70 ± 0.22	2
Antagonist	Butaclamol	0.43 ± 0.09	0.16 ± 0.01	0.4
	Haloperidol	0.30 ± 0.06	0.16 ± 0.02	0.5

n=2 to 4. The data shown is a mean ± SE of n=3 or 4, or in the case of n=2, then the mean of ± 1/2 range. [¹²⁵I]-7-OH-PIPAT binding was measured for dopamine D_{2L} receptor in the G-protein-coupled state, while [³H]-spiperone binding was measured for dopamine D_{2L} receptor in the G-protein-uncoupled state. (Reference 2)

3) Using the CHO cells expressing the recombinant human DA D₂ receptor, we conducted *in vitro* studies on spare receptors. Using the alkylating agent EEDQ to partially inactivate the DA D₂ receptor, at the concentration of EEDQ that has no effect on the maximum inhibitory effect on cAMP accumulation by DA, the maximum inhibitory effect of aripiprazole on cAMP accumulation decreased dramatically (10). These data indicate that spare DA receptors exist, while such receptors do not exist for aripiprazole. Thus, aripiprazole can be considered to be DA D₂ receptor partial agonist.

4) We studied the effect of aripiprazole *ex vivo* on the presynaptic DA D₂ autoreceptor, which regulates the activity of tyrosine hydroxylase, a rate-determining step in DA biosynthesis. Because the presynaptic DA D₂ autoreceptor has many spare receptors while the postsynaptic DA D₂ receptor has essentially no spare receptors, a DA D₂ receptor partial agonist acts as an agonist at the presynaptic site but as an antagonist and not as an agonist at the postsynaptic site (17,18). In animals treated with reserpine or γ -butyrolactone, aripiprazole, like the DA D₂ receptor partial agonist S-(-)-3-PPP (19), inhibited the increase in DA biosynthesis and showed DA D₂ autoreceptor agonist activity (11). These results indicate that aripiprazole is a DA D₂ receptor partial agonist.

REGULATION OF DOPAMINERGIC NEUROTRANSMISSION BY DA D₂ RECEPTOR PARTIAL AGONIST ACTIVITY

The DA D₂ receptor partial agonist activity is a characteristic that is not seen with the existing typical

or atypical antipsychotics, DA D₂ receptor antagonists. In contrast to the DA D₂ receptor antagonists that act generally at the DA D₂ receptor regardless of the activity of the *in vivo* dopaminergic neurotransmission and inhibit the action of DA at the D₂ receptor completely at a high dose, the DA D₂ receptor partial agonist acts as an antagonist at the DA D₂ receptor in the state of excessive dopaminergic neurotransmission, while it acts as an agonist at the DA D₂ receptor in the state of low dopaminergic neurotransmission (20). The *in vitro* and *in vivo* studies indicated that the DA D₂ receptor partial agonist aripiprazole acts as a DA D₂ receptor antagonist in the states of the excessive dopaminergic neurotransmission and as a DA D₂ receptor agonist in the state of the low dopaminergic neurotransmission (Figure 2) (10, 11, 21).

AFFINITY AND EFFECTS AT OTHER RECEPTORS

Table 2 shows the affinity of aripiprazole at various receptors. Aripiprazole has the highest affinity to the DA D₂ receptor, and also has high affinity to the DA D₃ receptor, and the serotonin 5-HT_{1A} and 5-HT_{2A} receptors. Aripiprazole also acts as a partial agonist at the D₃ receptor(12) and the 5-HT_{1A} receptor(22) and as an antagonist at the 5-HT_{2A} receptor(23). Aripiprazole at the serotonin 5-HT_{2A} receptor acts as a partial agonist with low intrinsic activity (12.7% of 5-HT), and at the serotonin 5-HT_{2B} receptor acts as an inverse agonist (12).

Aripiprazole has relatively high affinity to the serotonin 5-HT_{2A} receptor (Ki value : 3.4 nM), but

Figure 2 Agonist and antagonist activities of aripiprazole at the dopamine D₂ receptor using cAMP accumulation after forskolin stimulation as an index

In the presence of 10 μ M EEDQ, Chinese hamster ovary cells expressing the human dopamine D_{2L} receptor were incubated to partially inactivate the dopamine D₂ receptor. After removing the EEDQ by washing, the effect of aripiprazole on forskolin-induced cAMP accumulation was measured in the absence (■) and presence (▲) of dopamine at 100 nM. The data shown is the mean $\pm$ 1/2 range of 2 experiments. (Reference 2)

its affinity to the DA D₂ receptor is 10-fold higher (K_i value : 0.34 nM). The SDA-type antipsychotics have a relatively higher affinity to the 5-HT_{2A} receptor than to the D₂ receptor, and it has been hypothesized that this is a requirement for clinical utility as an atypical agent (8). According to this hypothesis, aripiprazole would not be an SDA-type agent. As far as we are aware, there have been 3 reports from different research institutions on the effect of aripiprazole on intracerebral DA release in the rat brain using the intracerebral microdialysis method. There are 2 reports involving the medial prefrontal cortex. One study reported that aripiprazole had no effect on DA release (24). In the other study, aripiprazole promoted DA release in the medial prefrontal cortex, but the DA release promoting effect was seen only at the intermediate dose among the 4 doses selected. The effect was mild and without dose-dependence (25). There is also 1 report on the frontal cortex; aripiprazole had a mild but dose-dependent effect of decreasing the DA release (26). There are 2 reports on the striatal system; in one report aripiprazole had no effect on DA release (24), while in the other there was a slight dose-dependent inhibition of the DA release (26). These data indicate that aripiprazole differs not only from the SDA-type antipsychotics but also the conventional antipsychotics in that it has essentially no effect of

promoting DA release from presynaptic sites. The lack of promotion of DA release by aripiprazole is postulated to be due to the presynaptic DA D₂ receptor autoreceptor agonist activity based on the DA D₂ receptor partial agonist activity.

Aripiprazole has low affinity to the adrenergic α_1 receptor involved in sedation and orthostatic hypotension and histamine H₁ receptor involved in sedation and weight gain, and extremely low affinity to the muscarinic receptor involved in anti-cholinergic side effects (visual disturbance, thirst, constipation, urination disorder, and cognitive disorder) (Table 2).

5 UTILITY OF ARIPIPAZOLE IN THE TREATMENT OF SCHIZOPHRENIA

In short-term placebo-controlled studies conducted overseas (27-29), aripiprazole improved positive and negative symptoms in patients with acute exacerbation, and prevented relapse in a 26-week long-term placebo-controlled study (30). In a 52-week long-term study (31), its improvement in positive symptoms was equivalent to haloperidol and was better against negative symptoms and depressive symptoms. It had a low incidence of extrapyramidal effects and was shown to have little effects on the blood prolactin level and weight gain, which have been seen with other agents (13, 14,

Table 2 Binding characteristics of antipsychotics

Receptor	Aripiprazole	Clozapine	Risperidone	Olanzapine	Quetiapine	Ziprasidone	Haloperidol
D ₁	265	290	580	52	1,300	130	120
D ₂	0.34	130	2.2	20	180	3.1	1.4
D ₃	0.8	240	9.6	50	940	7.2	2.5
D ₄	44	47	8.5	50	2,200	32	3.3
5-HT _{1A}	1.7	140	210	2,100	230	2.5	3,600
5-HT _{2A}	3.4	8.9	0.29	3.3	220	0.39	120
5-HT _{2C}	15	17	10	10	1,400	0.72	4,700
5-HT ₆	214	11	2,000	10	4,100	76	6,000
5-HT ₇	39	66	3.0	250	1,800	9.3	1,100
Alpha 1	57(rat)	4.0	1.4	54	15	13	4.7
Alpha 2	791(rat)	33	5.1	170	1,000	310	1,200
H ₁	61	1.8	19	2.8	8.7	47	440
M ₁	>10 μ M	1.8	2,800	4.7	100	5,100	1,600
	(IC ₅₀ ,bovine)						

Unless specifically noted, the values indicate the K_i value (nM) at the expressed human receptor. The K_i values (nM) for antipsychotics other than aripiprazole are taken from Reference 26.

32-35).

A hypothesis based on the pathophysiological research has suggested that the mesolimbic dopaminergic neurotransmission is in a hyperactivated state in schizophrenic patients (4-6). Antipsychotics have the DA D₂ receptor antagonist effect and improve positive symptoms by inhibiting the postsynaptic DA D₂ receptor in the mesolimbic dopaminergic neurons and at the same time have extrapyramidal side effects and hyperprolactinemia by inhibiting the postsynaptic DA D₂ receptor in the substantia nigra and tuberoinfundibular dopaminergic neurons respectively (4, 5). In schizophrenia, the mesolimbic dopaminergic neurotransmission is in a hyperactive state, while the tuberoinfundibular dopaminergic neurotransmission is in normal state and substantia nigra dopaminergic neurotransmission is actually in a suppressed state (6). In addition, it has been reported that postsynaptic DA D₂ receptors (D₂ receptor on the prolactin-secreting cells in the anterior pituitary) on the tuberoinfundibular dopaminergic neurons have spare receptors (36). Aripiprazole acts as an antagonist on the mesolimbic postsynaptic DA D₂ receptor and thus improves the positive symptoms by inhibiting the excessive dopaminergic neurotransmission. At the same time, it does not completely inhibit the neurotransmission at the postsynaptic DA D₂ receptor in the substantia nigra and also has no inhibitory effect at the postsynaptic DA D₂ receptor in the tuberoinfundibular system, so that there are less extrapyramidal side effects and no hyperprolactinemia. In schizophrenia, it is thought that the decreased dopaminergic neuro-

transmission in the prefrontal cortex leads to the expression of negative symptoms (6,7), and aripiprazole has agonist activity at the postsynaptic DA D₂ receptor in the prefrontal cortex in the state of low dopaminergic neurotransmission and improve the negative symptoms by improving the low neurotransmission.

REFERENCES

1. McClellan JM, Werry JS : Schizophrenia. *Psychiatr Clin North Am* 15 (1) : 131-48, 1992
2. Kornhuber J, Wiltfang J, Bleich S : The etiopathogenesis of schizophrenias. *Pharmacopsychiatry* 37 (Suppl 2) : S103-12, 2004
3. Nagashi M : Psychiatric diseases and dopamine. *Metabolism and Disease* 22 : 49-59, 1985
4. Carlsson A : Antipsychotic drugs, neurotransmitters, and schizophrenia. *Am J Psychiatry* 135 : 164-173, 1978
5. Levinson DF : Pharmacologic treatment of schizophrenia. *Clin Ther* 13 : 326-352, 1991
6. Risch SC : Pathophysiology of schizophrenia and the role of newer antipsychotics. *Pharmacotherapy* 16 (1 Pt 2) : 11S-14S, 1996
7. Weinberger DR : Implications of normal brain development for the pathogenesis of schizophrenia. *Arch Gen Psychiatry* 44 : 660-669, 1987
8. Ishigooka J : Trends in the development of future second generation antipsychotics. *Japanese Journal of Psychopharmacology* 4 : 1653-1664, 2001

9. Murasaki M : Prospects for new psychopharmacological therapy : a view from the development process of the novel antipsychotics. Japanese Journal of Psychopharmacology 1 : 5-22, 1998
10. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB : Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D₂ receptors. J Pharmacol Exp Ther 302 : 381-389, 2002
11. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S: 7-[4-[4(2, 3-Dichlorophenyl)-1-piperazinyl] butyloxy]-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D₂ receptor antagonistic activity. J Pharmacol Exp Ther 274 : 329-336, 1995
12. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R : Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuro-psychopharmacology 28 : 1400-1411, 2003
13. Harrison TS, Perry CM: Aripiprazole; a review of its use in schizophrenia and schizoaffective disorder. Drugs 64 : 1715-1736, 2004
14. McGavin JK, Goa KL : Aripiprazole. CNS Drugs 16 : 779-786, 2002
15. Miyamoto S, Duncan GE, Mailman RB, Lieberman JA: Developing novel antipsychotic drugs ; Strategies and goals. Current Opinion in CPNS Investigational Drugs 2 : 25-39, 2000
16. McDonald WM, Sibley DR, Kilpatrick BF, Caron MG: Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D₂ dopamine receptors. Mol Cell Endocrinol 36:201-209, 1984
17. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M : Relation-ship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31:592-598, 1987
18. Meller E, Enz A, Goldstein M : Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol 155 : 151-154, 1988
19. Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A, Nilsson LG : Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81 : 89-99, 1983
20. Coward D, Dixon K, Enz A, Shearman G, Urwyler S, White T, Karobath M: Partial brain dopamine D₂ receptor agonists in the treatment of schizophrenia. Psychopharmacology Bulletin 25 : 393-397, 1989
21. Inoue T, Domae M, Yamada K, Furukawa T : Effects of the novel antipsychotic agent 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy]-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137-143, 1996
22. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The anti-psychotic aripiprazole is a potent, partial agonist at the human 5-HT_{1A} receptor. Eur J Pharmacol 441 : 137-140, 2002
23. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T: Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psycho-pharmacol 18 : 375-383, 2004
24. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA : *In vivo* effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483 : 45-53, 2004
25. Li Z, Ichikawa J, Dai J, Meltzer HY: Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493 : 75-83, 2004
26. Semba J, Watanabe A, Kito S, Toru M: Behavioral and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791, 1995
27. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW : Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771, 2002
28. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia ; safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-126, 2003
29. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60 : 681-690, 2003
30. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG (Aripiprazole Study

- Group): Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. *J Clin Psychiatry* 64 : 1048-1056, 2003
31. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T : Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. *Int J Neuro-psychopharmacol* 6 : 325-337, 2003
  32. American Diabetes Association : Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care* 27 : 596-601, 2004
  33. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (Aripiprazole Study Group): A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. *Am J Psychiatry* 160 : 1651-1658, 2003
  34. Miyamoto S : Information of the latest antipsychotic : aripiprazole. *The Japanese Journal of Psychiatry* 9 : 257-261, 2004
  35. Nagashi M : Novelty of aripiprazole : a new dopamine D₂ receptor partial agonist for the treatment of schizophrenia. *Clinical Psychiatry* 46 : 855-864, 2004
  36. Meller E, Puza T, Miller JC, Friedhoff AJ, Schweitzer JW : Receptor reserve for D₂ dopaminergic inhibition of pro-lactin release *in vivo* and *in vitro*. *J Pharmacol Exp Ther* 257 : 668-675, 1991